Study: NCT06647563

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 60 Gray/day
Description: Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 60 Gray/day
Description: Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 60 Gray/day
Description: Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 66 Gray/day
Description: High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 66 Gray/day
Description: High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 66 Gray/day
Description: High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 70 Gray/day
Description: Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 70 Gray/day
Description: Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 70 Gray/day
Description: Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.